Buy generic drugs from our online pharmacy without prescription

0
You have no items in your shopping cart.

0

Welcome to our online store!

Buy Alfacip online without prescription

Quick Overview

Alfacip is used to treat osteoporosis and conditions with impairments of calcium metabolism such as bone loss due to age.

Availability:
in stock
Product #:
000133
Active ingredient:
Alfacalcidol
Available Dosage:
0.25 mg;0.5 mcg;
Do I need a prescription?:
No, when purchased online
Payment options:
VISA, Mastercard, American Express, Diners Club, Jcb card and cryptocurrency (Bitcoin, Ethereum)
Delivery time:
Trackable Courier Service, 5-9 days, International Unregistered Mail, 14-21 days
Delivery to countries:
worldwide, including United Kingdom, Australia and USA

Alfacip 0.25 mg Price

Package Price Per Pill  
30 pills x 0.25 mg $ 80.99 $ 2.7
60 pills x 0.25 mg $ 133.99 $ 2.23
90 pills x 0.25 mg $ 186.99 $ 2.08
120 pills x 0.25 mg
+Free International Unregistered Mail
$ 210.99 $ 1.76
240 pills x 0.25 mg
+Free International Unregistered Mail
$ 383.99 $ 1.6

Alfacip 0.5 mcg Price

Package Price Per Pill  
30 pills x 0.5 mcg
+Free International Unregistered Mail
$ 238.99 $ 7.97
60 pills x 0.5 mcg
+Free International Unregistered Mail
$ 397.99 $ 6.63
90 pills x 0.5 mcg
+Free International Unregistered Mail
$ 550.99 $ 6.12
120 pills x 0.5 mcg
+Free International Unregistered Mail
$ 673.99 $ 5.62
240 pills x 0.5 mcg
+Free International Unregistered Mail
$ 1224.99 $ 5.1

Product information

Alfacip is the active ingredient in many drugs including those used to treat osteoporosis, diabetes mellitus, high blood pressure, osteopenia and the common cold. Alfacip has been shown to be a powerful antioxidant and may protect against oxidative and inflammatory conditions. Dosing of this supplement should be made according to your specific medical condition and the dose and frequency of administration will need to be monitored carefully. In addition to its active ingredient, Alfacip is also used in various forms to treat conditions with impairments of calcium metabolism such as osteoporosis and hypoparathyroidism. Alfacip has been found to be effective in treating osteoporosis and hypoplastic anaemia. Alfa-Alp (Alfa Alp) is a non-nutritive sweetener found in many foods and beverages. It is a source of calcium, magnesium, zinc and vitamin A. It is also a source of vitamin C and vitamin D, and its effects on the nervous system are beneficial to the body. The amount of Alfacip in Alfacap is determined by the amount of Alfacip present in the food Alfacip has beneficial effects on the development of osteoporosis in humans. Osteoporosis: a health problem of the bones? The term "Osteoporosis" is used by the American Academy of Osteopathic Medicine to refer to diseases of the bones and joint systems that result from abnormal bone mineralization, including osteoarthritis, lumbar degeneration and spinal cord injury. A number of medical conditions associated with abnormal bone mineralization also include osteopenia (a lack of normal bone growth), osteoporosis and osteoporosis-induced fractures, osteopenia-associated osteoporosis and hip and knee osteoporosis. Osteoporosis may be the result of a number of different factors, including: Bone loss caused by aging or poor diet, or by disease, surgery, radiation and/or other physical damage to the bones; Osteomalacia, an accumulation of mineralized bone, that develops over time; The presence of low concentrations of calcium in the body; The lack of adequate vitamin D in the diet; A lack of adequate vitamin B6, The primary objective of ALFAC is to reduce bone loss caused by age-related osteoporosis. The aim is to reduce bone loss caused by renal osteopyrophy, hyperparathyroidism (a disorder with parathyroid hormone deficiency, the substance required for the absorption of calcium and phosphorus), hypoparathyroidism, neonatal hypocalcaemia, nutritional and malabsorptive rickets and osteomalacia, pseudo-deficiency (D-dependent) rickets and osteomalacia, hypophosphataemic vitamin D resistant rickets and osteomalacia, osteoporosis. Alfacip can be administered to patients aged ≥18 y who have not had any renal disease or other renal dysfunction or who have no known clinical renal disease and who also do not have any clinical renal disease. In addition, patients with a documented history of clinical renal disease are eligible for this treatment. Alfacip is also recommended for the treatment of osteoporosis with calcium deficiency. In patients with calcium deficiency, Alfacip is also prescribed by physicians to assist in maintaining adequate calcium levels and is also used in the treatment of bone fractures of various types. Alfacip can also be administered for the treatment of calcium deficiency, which is a condition of low calcium. The treatment with Alfacip is not associated with side effects such as dizziness, headache, nausea, vomiting, fatigue, blurred vision and drowsiness. Alfacip is also used for the treatment of osteoporosis, where calcium has been lost from skeletal tissue due to osteoporosis. The treatment is associated with bone loss as well. In patients with renal disease, Alfacip is also given to treat calcium deficiency. In patients with osteoporosis, the amount of calcium in the blood is reduced and the calcium levels drop to less than the normal value. Dosage Alfacip can be given to patients who are already receiving calcimoroid-based therapies. The daily dosage of Alfacip is between 1,000 – 8,000 mg Alfacip is also used to treat patients with diabetes mellitus and hyperlipidemia. A multicomponent treatment program includes treatment with Alfacip, vitamin D, and calcium. Dose Alfacip (5 mg, 2 capsules) is used to treat osteoporosis, hyperparathyroidism, diabetic ketoacidosis, hyperkalemia, hyperphosphatemia, hyperphosphatemia, hypoparathyroidism, osteoporosis, and diabetes mellitus. Usual Adult Dose for Adults: For patients taking calcium-containing drugs and vitamin D-containing medications, the dose is approximately 2 capsules daily or about 1,000 international units. For patients taking diuretics and hypothyroid medications, the dose is approximately 1,100 international units (international units = one US teaspoon). For patients taking vitamin K1/K2 supplements, the dose is approximately 2 capsules daily, or about 500 international units (international units = 10,000 international units) for adults. For patients using calcium-containing medications and vitamin D-containing medications, the dose is approximately 2,000 international units ( Alfacip also may be used for the treatment of osteoporosis and bone fractures in persons at high risk for developing such complications and/or for those with osteoporosis who are not receiving other calcium supplements.[1] Alfacip is used to reduce calcium absorption, but it is not absorbed at levels sufficient to cause serious problems with calcium absorption in the long term.[1] It has the potential to cause renal bone loss in persons who do not get adequate calcium intake, as this is the most common cause of osteomalacia.[1] There have been reports of people who take Alfacip for a long time having a significant increase in osteoporotic fractures.[1] Alfacip can also be used as an alternative to calcium supplements, but not without potential problems. It is not recommended that Alfacip should be taken daily. It may be more convenient if the supplement is taken twice per week. Alfacip can be used with calcium supplements, and should not be used with calcium supplementation that is not calcium-rich.[2] Alfacip is not an anti-depressant. Evaluation of the clinical efficacy of Alfacip in combination with other drugs has shown a clear advantage of its combination with the other drug, with a mean of 0.9 months shorter duration of treatment compared to Alfacip alone. In contrast, in studies using the other two drugs (e.g. calcium acetate and calcium phosphate, in combination, in the treatment of bone loss due to age), it took an average of 5.5 months longer to complete the first stage of treatment when compared to Alfacip alone. It also took an average of 5.4 months longer to complete the second stage of treatment when compared to Alfacip alone. The study also showed increased rates of bone loss due to osteoporosis and fractures, particularly in the legs, and an increase in risk for fractures, particularly hip fractures when using Alfacip compared to calcium acetate. It has also been demonstrated that Alfacip has the potential to treat other conditions that cause osteoporosis or osteoporotic fractures such as rickets, hyperparathyroidism and hypoplasia. Alfacip has also been shown to reduce the incidence and severity of osteoporosis and to treat Alfacip can be given in a tablet form, a capsule form, a syrup form, in liquid form and in gel form. The tablet form is preferred as the dose is not as high and is more suitable for patients who require continuous monitoring and who may not be able to use other forms. The capsules are used to treat conditions such as: calcium hypophosphatemia, hypo-parephalinemia, hypomagnesemia, osteoporosis, hypogonadism and osteomalacia. The liquid form of Alfacip may also provide some benefits to some patients. In the liquid form Alfacip can be administered as a gel tablet for up to 4 weeks after treatment or as a cream (or ointment) for up to 2 weeks following treatment. Alfacip has been shown to work well as part of a combination of a calcium supplement, a calcium gluconate, and a calcium-phosphate supplement. Alfacip is used in children and adults to manage calcium deficiency. It is also used to treat osteoporosis, osteomalacia and other conditions with impaired calcium metabolism such as osteoporosis, osteoporosis/ Dosage should be divided into four doses: 1 g/kg daily (1 g/day is enough in young children to maintain an increase in bone mass, but is not necessary for adult patients) 2 g/day (4 g/day is necessary in adults) 4 g/day (12 mg/day is necessary in infants and children) Dosage may be divided to achieve a maximum effect (1 g is sufficient in adults to maintain an increase in bone mass, but is not necessary for adults). Dosage should therefore be divided according to the age of the patient, and should be adjusted according to individual risk factors. For example, if a dose of 1 g is necessary for young adult patients to maintain an increase in bone mass, and an additional dose of 2 g for older adults, then dosage would be 2 g/day for young adult, and 4 g/day for older adult. Dosage should not be adjusted as a consequence of treatment of an underlying disease.
More info loading...